A cannabinoid CB 1 receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy)

Neuropsychopharmacology

Volumn 35, Issue 2, 2010, Pages 515-520

  Nawata, Yoko ^a   Hiranita, Takato ^a,b   Yamamoto, Tsuneyuki ^a  

^a NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cannabinoid CB1 receptors; Hippocampus; MDMA; Novel object recognition task; Recognition memory; Withdrawal

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG WITHDRAWAL; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECOGNITION; TASK PERFORMANCE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GENE EXPRESSION REGULATION; HALLUCINOGENS; HIPPOCAMPUS; MALE; MEMORY DISORDERS; MICE; MICE, KNOCKOUT; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECOGNITION (PSYCHOLOGY); SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 72449162513     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.158     Document Type: Article

References (36)

1. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S et al (2004). Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29: 1470-1478.
2. Broadbent NJ, Squire LR, Clark RE (2004). Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci USA 101: 14515-14520.
3. Clark RE, Zola SM, Squire LR (2000). Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20: 8853-8860.
4. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M et al (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118: 61-65.
5. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ (2006). Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacol-ogy 31: 1036-1047.
6. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA (2002). Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 66: 77-84.
7. Hampson RE, Deadwyler SA (2000). Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 20: 8932-8942.
8. Hiranita T, Nawata Y, Sakimura K, Yamamoto T (2008). Methamphetamine- seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology 55: 1300-1306.
9. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR (2007). Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentia-tion. Learn Mem 14: 63-74.
10. Kosiorek P, Hryniewicz A, Bialuk I, Zawadzka A, Winnicka MM (2003). Cannabinoids alter recognition memory in rats. Pol J Pharmacol 55: 903-910.
11. Li S, Cullen WK, Anwyl R, Rowan MJ (2003). Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nat Neurosci 6: 526-531.
12. Lichtman AH, Martin BR (1996). Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126: 125-131.
13. Mackie K (2008). Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol 286: S60-S65.
14. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004). Chronic MDMA (ecstasy) use, cognition and mood. Psycho-pharmacology 173: 434-439.
15. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM et al (2003). Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: drug-induced hyperther-mia does not predict long-term outcomes. Psychopharmacology 168: 465-474.
16. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF (2007). Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 13: 807-820.
17. Misner DL, Sullivan JM (1999). Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19: 6795-6805.
18. Mitrirattanakul S, Lopez-Valdes HE, Liang J, Matsuka Y, Mackie K, Faull KF et al (2007). Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin Exp Res 31: 855-867.
19. Miyamoto A, Yamamoto T, Watanabe S (1995). Effect of repeated administration of delta 9-tetrahydrocannabinol on delayed match-ing-to-sample performance in rats. Neurosci Lett 201: 139-142.
20. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('ecstasy'). Eur J Pharmacol 433: 91-99.
21. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC et al (2002). Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26: 802-816.
22. Pace-Schott EF, Morgan PT, Malison RT, Hart CL, Edgar C, Walker M et al (2008). Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence. Am J Drug Alcohol Abuse 34: 109-121.
23. Piper BJ, Meyer JS (2004). Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79: 723-731.
24. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N et al (2008). Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113-1126.
25. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9: 1526-1533.
26. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572.
27. Schneider M, Koch M (2002). The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13: 29-37.
28. Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M et al (2005). Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30: 1670-1680.
29. Suenaga T, Ichitani Y (2008). Effects of hippocampal administration of a cannabinoid receptor agonist WIN 55,212-2 on spontaneous object and place recognition in rats. Behav Brain Res 190: 248-252.
30. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005). Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 164: 206-213.
31. Touriño C, Ledent C, Maldonado R, Valverde O (2008). CB1 cannabinoid receptor modulates 3,4-methylenedioxymetham-phetamine acute responses and reinforcement. Biol Psychiatry 63: 1030-1038.
32. Ward J, Hall K, Haslam C (2006). Patterns of memory dysfunction in current and 2-year abstinent MDMA users. J Clin Exp Neuropsychol 28: 306-324.
33. Wareing M, Fisk JE, Montgomery C, Murphy PN, Chandler MD (2007). Information processing speed in ecstasy (MDMA) users. Hum Psychopharmacol 22: 81-88.
34. Yamaguchi T, Kubota T, Watanabe S, Yamamoto T (2004). Activation of brain prostanoid EP3 receptors via arachidonic acid cascade during behavioral suppression induced by Delta8-tetrahydrocannabinol. J Neurochem 88: 148-154.
35. Yamamoto T, Takada K (2000). Role of cannabinoid receptor in the brain as it relates to drug reward. Jpn J Pharmacol 84: 229-236.
36. Yamamoto T, Anggadiredja K, Hiranita T (2004). New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid- arachidonic acid pathway in drug reward and long-lasting relapse to drug taking. J Pharmacol Sci 96: 382-388.